All In Biotech

Drug Trial Radar · NCT07164183

Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis

Prospective, Multicenter, Open-label, Randomized, Parallel Groups Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules (LLC Alcea, Russia) and Visanne 2 mg Tablets (BAYER AG, Germany) in Treatment of Endometriosis

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Sep 11, 2025

Primary completion

Oct 2026

Study completion Nov 2026

Sponsor

Lead sponsor
AlceaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective open-label randomized parallel groups study to compare efficacy and safety of Indinol Forto® 200 mg capsules and Visanne 2 mg tablets in treatment of endometriosis. This is phase 3 study, based on hypothesis of non-inferiority.

Conditions

  • Endometriosis

Interventions

  • Indole-3-carbinolDrug

    Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks

  • DienogestDrug

    Visanne (dienogest) 2 mg tablets orally once a day during 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average daily pelvic pain score, combinedTime frame: Visit 7 (week 24)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Kazan', Russia · Not yet recruiting

  • Research Site

    Moscow, Russia · Not yet recruiting

  • Research Site

    Rostov-on-Don, Russia · Not yet recruiting

  • Research Site

    Ryazan, Russia · Recruiting

  • Research Site

    Saint Petersburg, Russia · Not yet recruiting

  • Research Site

    Smolensk, Russia · Recruiting

  • Research Site

    Tver', Russia · Not yet recruiting

  • Research Site

    Yaroslavl, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.